

Howard A. Zucker, M.D., J.D. Acting Commissioner of Health

Sue Kelly Executive Deputy Commissioner

Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective September 16, 2014, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

Cymbalta and Vancocin will be removed from the Program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program do not require the submission of Dispense as Written/Product Selection Code of '1'; Pharmacies can submit any valid NCPDP field (408-D8) value.

List of Brand Name Drugs included in this program* (Updated 9/2/14):

Accolate	Evista	Prograf
Adderall XR	Felbatol	Pulmicort Respules
Alphagan P 0.15%	Focalin XR(15mg,30mg,45mg)	Solaraze
Aldara	Gabitril 2mg, 4mg	Soriatane
Astepro	Hepsera	Symbyax
Bactroban cream	Kadian	Tegretol suspension
Carbatrol	Lidoderm	TOBI
Catapres-TTS	Lovenox	Tobradex
Combivir	Mepron	Toprol XL
Depakote sprinkle	Myfortic	Trileptal suspension
Diastat	Niaspan	Trizivir
Diovan HCT	Ortho Evra	Wellbutrin
Epivir HBV	Prevpac	Wellbutrin XL

^{*}List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.

